The short answer
Kava is best avoided alongside valproate unless the treating clinician specifically reviews its use. Federal guidance advises against combining kava with sedating substances, and valproate can cause sedation. The magnitude of this particular interaction is not known.
What this answer covers
Oral Piper methysticum beverages and extracts; extraction method, plant material and co-ingredients matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- valproate
Why avoidance is advised
NCCIH advises against taking kava with other substances that have sedative effects. Valproate can cause drowsiness and impaired thinking, especially with other nervous-system depressants. The precaution follows those two sources; it is not a measured rate of valproate-kava toxicity.
Liver concerns are separate
Kava products have been linked to rare serious liver injury. Valproate also carries its own important liver warning. This overlap adds a reason for careful review, but the separate reports do not prove that the combination multiplies liver risk or establish a particular monitoring schedule.
Water preparations are not exempt
Reported liver cases have involved solvent extracts and water-prepared beverages. Product differences therefore matter, but an aqueous preparation cannot simply be assumed risk-free. A blend may also contain other sedating ingredients.
Spacing is not a proven solution
Taking kava and valproate a few hours apart has not been shown to prevent impairment. Discuss any current kava use with the prescriber rather than changing prescribed valproate yourself. New marked drowsiness or confusion needs assessment; do not drive while impaired.
Evidence and practical considerations
Timing & monitoring
Avoidance is supported as an indirect precaution from kava sedative guidance and the valproate label; no protective separation interval is established.
- Exact scope
- Oral Piper methysticum beverages and extracts; extraction method, plant material and co-ingredients matter. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Research assessment: · Open full citations ↗
Side effects & toxicity
Possible additive sedation is supported as a precaution, without demonstrated valproate-kava toxicity magnitude.
- Exact scope
- Oral Piper methysticum beverages and extracts; extraction method, plant material and co-ingredients matter. with Oral valproate active moiety (RxNorm 40254 IN), with formulation boundaries preserved.
- Medication form and route
- oral valproate; oral supplement
What remains uncertain
- Evidence does not quantify all-product interaction risk; source-specific limits apply.
Factors that may matter: Indication; Exact preparation; Other sedating medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral valproic acid; valproate somnolence trial in elderly dementia patients.
Valproate may impair alertness, especially with other CNS depressants. Older adults may have more somnolence. Major metabolic pathways are glucuronidation and beta-oxidation; CYP oxidation is relatively minor. Serious liver injury is an intrinsic risk.
How this applies: Explicit oral active-moiety bridge to RxNorm IN 40254 valproate; no dose conversion or intravenous extrapolation.
No named interaction with the seven supplements. Active-moiety relevance does not establish identical kinetics or dosing for every valproate formulation.
Source 2: federal supplement safety guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: Users of the specified supplement.
Kava should not be used with other sedating substances. Various kava products have been linked to rare liver injury, sometimes serious or fatal.
How this applies: Supplement-only guidance interpreted alongside the medication label.
Does not quantify a valproate interaction or establish protective dose spacing.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared article with direct-study limits, preparation boundaries and claim-specific conclusions. | |
| Research summary published |
Article revision: b17844afb8ffe7a1
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.